Literature DB >> 9445065

Foamy virus particle formation.

N Fischer1, M Heinkelein, D Lindemann, J Enssle, C Baum, E Werder, H Zentgraf, J G Müller, A Rethwilm.   

Abstract

Subgenomic expression plasmids for the so-called human foamy virus (HFV) structural gag, gag/pol, and env genes were constructed and used to analyze foamy virus particle formation by electron microscopy. Expression of an R-U5-gag-pol construct under control of the human cytomegalovirus immediate-early enhancer-promoter resulted in the formation of viral cores with a homogeneous size of approximately 50 nm located in the cytoplasm. Upon coexpression of an envelope construct, particles were observed budding into cytoplasmic vesicles and from the plasma membrane. Expression of the Gag protein precursor pr74 alone led to aberrantly formed viral particles of heterogeneous size and with open cores. Normal-shaped cores were seen after transfection of a construct expressing the p70gag cleavage product, indicating that p70gag is able to assemble into capsids. Coexpression of p70gag and Env resulted in budding virions, ruling out a requirement of the reverse transcriptase for capsid or virion formation. In sharp contrast to other retroviruses, the HFV cores did not spontaneously bud from cellular membranes. Radiochemical labeling followed by protein gel electrophoresis also revealed the intracellular retention of Env-deprived HFV capsids.

Entities:  

Mesh:

Year:  1998        PMID: 9445065      PMCID: PMC124643     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription.

Authors:  R C Hirsch; J E Lavine; L J Chang; H E Varmus; D Ganem
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

Review 2.  Assembly of hepadnaviral virions and subviral particles.

Authors:  D Ganem
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

3.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

4.  Characterization of a human foamy virus 170-kilodalton Env-Bet fusion protein generated by alternative splicing.

Authors:  D Lindemann; A Rethwilm
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Novel N-terminal amino acid sequence required for retention of a hepatitis B virus glycoprotein in the endoplasmic reticulum.

Authors:  K Kuroki; R Russnak; D Ganem
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

6.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

Review 7.  The intracisternal A-particle gene family: structure and functional aspects.

Authors:  E L Kuff; K K Lueders
Journal:  Adv Cancer Res       Date:  1988       Impact factor: 6.242

8.  Identification of the major immunogenic structural proteins of human foamy virus.

Authors:  K O Netzer; A Rethwilm; B Maurer; V ter Meulen
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

9.  Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus.

Authors:  B Maurer; H Bannert; G Darai; R M Flügel
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

10.  The role of envelope proteins in hepatitis B virus assembly.

Authors:  V Bruss; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  70 in total

1.  Endogenous virus of BHK-21 cells complicates electron microscopy studies of foamy virus maturation.

Authors:  G Wang; M J Mulligan; D N Baldwin; M L Linial
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.

Authors:  P A Goepfert; K Shaw; G Wang; A Bansal; B H Edwards; M J Mulligan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.

Authors:  M Heinkelein; J Thurow; M Dressler; H Imrich; D Neumann-Haefelin; M O McClure; A Rethwilm
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  The intact retroviral Env glycoprotein of human foamy virus is a trimer.

Authors:  T Wilk; F de Haas; A Wagner; T Rutten; S Fuller; R M Flügel; M Löchelt
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression.

Authors:  Carolyn R Stenbak; Maxine L Linial
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Foamy virus Pol protein expressed as a Gag-Pol fusion retains enzymatic activities, allowing for infectious virus production.

Authors:  Eun-Gyung Lee; Amber Sinicrope; Dana L Jackson; Shuyuarn F Yu; Maxine L Linial
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

Review 7.  Molecular biology of foamy viruses.

Authors:  Axel Rethwilm
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

8.  Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity.

Authors:  Annett Stange; Ingrid Mannigel; Katrin Peters; Martin Heinkelein; Nicole Stanke; Marc Cartellieri; Heinrich Göttlinger; Axel Rethwilm; Hanswalter Zentgraf; Dirk Lindemann
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

9.  Identification of domains in gag important for prototypic foamy virus egress.

Authors:  Gillian S Patton; Stephen A Morris; Wayne Chung; Paul D Bieniasz; Myra O McClure
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

10.  RNA and protein requirements for incorporation of the Pol protein into foamy virus particles.

Authors:  Katrin Peters; Tatiana Wiktorowicz; Martin Heinkelein; Axel Rethwilm
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.